Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 23138000)

1.

The hazards of cross comparing the drug toxicity results from different trials in metastatic renal cancer: in response to a letter from Dr. Catalá-López.

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb S, Shamash J, Stockdale A, Lim L, Nathan P, Chowdury S.

Eur J Cancer. 2013 Mar;49(4):986-7. doi: 10.1016/j.ejca.2012.10.010. Epub 2012 Nov 5. No abstract available.

PMID:
23138000
2.

Safety of multikinase inhibitors in metastatic renal cell carcinoma and indirect treatment comparisons.

Catalá-López F.

Eur J Cancer. 2013 Mar;49(4):984-5. doi: 10.1016/j.ejca.2012.10.011. Epub 2012 Nov 6. No abstract available.

PMID:
23140823
3.

An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer.

Powles T, Sarwar N, Jones R, Wilson P, Boleti E, Protheroe A, Crabb SJ, Shamash J, Stockdale A, Rashid S, Nathan P, Chowdury S.

Eur J Cancer. 2012 Nov;48(17):3171-6. doi: 10.1016/j.ejca.2012.05.022. Epub 2012 Jul 4.

PMID:
22766517
4.

PISCES: a horoscope for first-line targeted therapy of metastatic renal cell carcinoma.

Sun M, Larcher A, Schiffmann J, Karakiewicz PI.

J Clin Oncol. 2014 Nov 20;32(33):3783. doi: 10.1200/JCO.2014.57.4673. Epub 2014 Sep 29. No abstract available.

PMID:
25267763
5.

Kidney cancer: in crossover study, patients and physicians prefer pazopanib.

Phillips R.

Nat Rev Urol. 2014 May;11(5):246. doi: 10.1038/nrurol.2014.87. Epub 2014 Apr 15. No abstract available.

PMID:
24731995
6.

How to interpret patient preferences in selecting the best drug: are the current measurements up to the job?

Garnick MB.

J Clin Oncol. 2014 May 10;32(14):1392-3. doi: 10.1200/JCO.2014.55.1911. Epub 2014 Mar 31. No abstract available.

7.

PISCES trial: the end does not always justify the means.

Barni S, Petrelli F.

J Clin Oncol. 2014 Nov 20;32(33):3782-3. doi: 10.1200/JCO.2014.56.8832. Epub 2014 Sep 29. No abstract available.

PMID:
25267749
8.

Reply to S. Barni et Al and M. Sun et Al.

Garnick MB.

J Clin Oncol. 2014 Nov 20;32(33):3785. doi: 10.1200/JCO.2014.57.9227. Epub 2014 Sep 29. No abstract available.

PMID:
25267752
9.

Reply to S. Barni et Al and M. Sun et Al.

Escudier B, Porta C, Powles T, Eisen T, Sternberg CN, Mehmud F, Cella D.

J Clin Oncol. 2014 Nov 20;32(33):3783-4. doi: 10.1200/JCO.2014.57.9219. Epub 2014 Sep 29. No abstract available.

PMID:
25267750
10.

Pazopanib outscores sunitinib on tolerability.

[No authors listed]

Cancer Discov. 2014 Jan;4(1):OF8. doi: 10.1158/2159-8290.CD-NB2013-131. Epub 2013 Sep 19.

11.

Efficacy and toxicity of sunitinib in patients with metastatic renal cell carcinoma with severe renal impairment or on haemodialysis.

O'Donnell PH.

BJU Int. 2011 Oct;108(8):1284-5. doi: 10.1111/j.1464-410X.2011.10179.x. Epub 2011 Mar 18. No abstract available.

PMID:
21418138
12.

Tolerance of sunitinib in dialyzed patients with metastatic renal cell carcinoma.

Vickers MM, Heng DY, Hemmelgarn B, Eigl BJ.

Clin Genitourin Cancer. 2009 Oct;7(3):E104-6. doi: 10.3816/CGC.2009.n.035.

PMID:
19815480
13.

Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma.

Park S, Lee J, Park SH, Park JO, Kang WK, Park YS, Cho JH, Lim HY.

Chemotherapy. 2010;56(6):485-91. doi: 10.1159/000321033. Epub 2010 Nov 24.

PMID:
21099221
14.

Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.

Lamarca A, Feliu J, Barriuso J.

Br J Cancer. 2012 Mar 13;106(6):1246. doi: 10.1038/bjc.2012.25. Epub 2012 Jan 31. No abstract available.

15.

Severe rhabdomyolysis during sunitinib treatment of metastatic renal cell carcinoma. A report of two cases.

Ruggeri EM, Cecere FL, Moscetti L, Doni L, Padalino D, Di Costanzo F.

Ann Oncol. 2010 Sep;21(9):1926-7. doi: 10.1093/annonc/mdq395. No abstract available.

16.

Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.

van den Meiracker AH, Danser AH, Sleijfer S, Kappers MH.

J Natl Cancer Inst. 2011 Oct 19;103(20):1557; author reply 1558. doi: 10.1093/jnci/djr328. Epub 2011 Aug 23. No abstract available.

17.

Hypertension as a predictive factor of Sunitinib activity.

Rixe O, Billemont B, Izzedine H.

Ann Oncol. 2007 Jun;18(6):1117. No abstract available.

18.

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer.

Kalantari HR.

Br J Cancer. 2009 Oct 6;101(7):1222-3; author reply 1224. doi: 10.1038/sj.bjc.6605303. Epub 2009 Sep 15. No abstract available.

19.

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

Feldman DR, Martorella AJ, Robbins RJ, Motzer RJ.

J Natl Cancer Inst. 2007 Jun 20;99(12):974-5; author reply 976-7. Epub 2007 Jun 12. No abstract available.

20.

Re: Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.

Garfield DH, Hercbergs A, Davis PJ.

J Natl Cancer Inst. 2007 Jun 20;99(12):975-6; author reply 976-7. Epub 2007 Jun 12. No abstract available.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk